Enliven Therapeutics ELVN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's cash & equivalents?
- Enliven Therapeutics (ELVN) reported cash & equivalents of $132.18M in Q1 2026.
- How has Enliven Therapeutics's cash & equivalents changed year-over-year?
- Enliven Therapeutics's cash & equivalents increased by 30.0% year-over-year, from $101.71M to $132.18M.
- What is the long-term trend for Enliven Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Enliven Therapeutics's cash & equivalents has grown at a 15.7% compound annual growth rate (CAGR), from $47.7M to $98.9M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.